Intellia Therapeutics released additional positive data for its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) in a Phase 3 trial for hereditary angioedema (HAE). The company said the study not only met its primary endpoint earlier but also achieved secondary endpoints with statistical and clinical significance. The company’s update arrives about six weeks after Intellia reported primary endpoint achievement for its one-time HAE treatment approach using in vivo editing. HAE is driven by dysregulation of the C1 inhibitor pathway, and current management depends on episodic or prophylactic therapies. Investors and clinicians are focused on how comprehensive these secondary outcomes are across patient subgroups and durability, since a one-and-done therapy could change the standard of care if benefits are sustained.